Literature DB >> 1372103

Identification of splicing mutations of the last nucleotides of exons, a nonsense mutation, and a missense mutation of the XPAC gene as causes of group A xeroderma pigmentosum.

I Satokata1, K Tanaka, S Yuba, Y Okada.   

Abstract

Four mutations of the XPAC gene were identified as molecular bases of different UV-sensitive subgroups of xeroderma pigmentosum (XP) group A. One was a G to C transversion at the last nucleotide of exon 4 in GM1630/GM2062, a little less hypersensitive subgroup than the most sensitive XP2OS/XP12RO. The second mutation was a G to A transition at the last nucleotide of exon 3 in GM2033/GM2090, an intermediate subgroup. Both mutations caused almost complete inactivation of the canonical 5' splice donor site and aberrant RNA splicing. The third mutation was a nucleotide transition altering the Arg-211 codon (CGA) to a nonsense codon (TGA) in another allele of GM2062. The fourth mutation was a nucleotide transversion altering the His-244 codon (CAT) to an Arg codon (CGT) in XP8LO, an intermediate subgroup. Our results strongly suggest that the clinical heterogeneity in XP-A is due to different mutations in the XPAC gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372103     DOI: 10.1016/0921-8777(92)90081-d

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  10 in total

1.  Use of Big Data to Estimate Prevalence of Defective DNA Repair Variants in the US Population.

Authors:  Jennifer Pugh; Sikandar G Khan; Deborah Tamura; Alisa M Goldstein; Maria Teresa Landi; John J DiGiovanna; Kenneth H Kraemer
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

2.  Diagnosis of Xeroderma Pigmentosum and Related DNA Repair-Deficient Cutaneous Diseases.

Authors:  James E Cleaver
Journal:  Curr Med Lit Dermatol       Date:  2008

3.  Xeroderma pigmentosum group C in an isolated region of Guatemala.

Authors:  James E Cleaver; Luzviminda Feeney; Jean Y Tang; Peggy Tuttle
Journal:  J Invest Dermatol       Date:  2006-09-21       Impact factor: 8.551

4.  Domains in the XPA protein important in its role as a processivity factor.

Authors:  Claudine L Bartels; Muriel W Lambert
Journal:  Biochem Biophys Res Commun       Date:  2007-03-02       Impact factor: 3.575

5.  Structural insights into the recognition of cisplatin and AAF-dG lesion by Rad14 (XPA).

Authors:  Sandra C Koch; Jochen Kuper; Karola L Gasteiger; Nina Simon; Ralf Strasser; David Eisen; Simon Geiger; Sabine Schneider; Caroline Kisker; Thomas Carell
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

6.  Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis.

Authors:  Zachary D Nagel; Carrie M Margulies; Isaac A Chaim; Siobhan K McRee; Patrizia Mazzucato; Anwaar Ahmad; Ryan P Abo; Vincent L Butty; Anthony L Forget; Leona D Samson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-22       Impact factor: 11.205

Review 7.  The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein.

Authors:  J E Cleaver; J C States
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

8.  Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy.

Authors:  R De Gasperi; M A Gama Sosa; E L Sartorato; S Battistini; H MacFarlane; J F Gusella; W Krivit; E H Kolodny
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

9.  High prevalence of the point mutation in exon 6 of the xeroderma pigmentosum group A-complementing (XPAC) gene in xeroderma pigmentosum group A patients in Tunisia.

Authors:  C Nishigori; M Zghal; T Yagi; S Imamura; M R Komoun; H Takebe
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

10.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Authors:  M Dabholkar; J Vionnet; F Bostick-Bruton; J J Yu; E Reed
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.